首页>
外国专利>
BIOMARKERS, USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION, AND IMMUNOTHERAPY METHODS
BIOMARKERS, USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION, AND IMMUNOTHERAPY METHODS
展开▼
机译:生物标志物,其用途用于选择免疫疗法干预,以及免疫疗法方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
The instant disclosure provides biomarkers and methods for identifying subjects at risk of relapse or suitable for allogeneic hematopoietic stem cell transplant after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. Exemplary biomarkers include pre-lymphodepletion levels of serum lactate dehydrogenase (LDH), pre-lymphodepletion levels of platelets, levels of MCP-1, levels of IL-17, and pre-treatment regimen disease pathology. Based on the determined risk-relapse profile, an at-risk subject may be treated with pre-emptive therapy, while a subject not at risk for relapse may not receive further treatment, or may receive an allogeneic hematopoietic stem cell transplant. Also provided are methods for treating a hematological malignancy, wherein certain embodiments of the methods comprise adoptive cell therapy in the context of BTK-inhibitor therapy and/or BTK-inhibitor therapy in the context of adoptive cell therapy. Also provided are methods for treating follicular lymphoma (FL).
展开▼